Treatment for Adolescents with Depression Study (TADS): Rationale, design, and methods

John March, Susan Silva, Stephen Petrycki, John Curry, Karen Wells, John Fairbank, Barbara Burns, Marisa Domino, Benedetto Vitiello, Joanne Severe, Charles Casat, Jeanette Kolker, Norah Feeny, Robert L Findling, Sheridan Stull, Susan Baab, Bruce Waslick, Michael Sweeney, Lisa Kentgen, Rachel KandelJohn Walkup, Golda Ginsburg, Elizabeth Kastelik, Hyung Koo, Christopher Kratochvil, Diane May, Randy LaGrone, Martin Harrington, Anne Marie Albano, Glenn Hirsch, Tracey Knibbs, Emlyn Capili, Mark Reinecke, Bennett Leventhal, Catherine Nageotte, Gregory Rogers, Sanjeev Pathak, Floyd Sallee, Elizabeth Cottingham, Jennifer Wells, Paul Rohde, Anne Simons, James Grimm, Katholiki Hadjiyannakis, Elizabeth Weller, Michele Robins, Ronald Weller, Naushad Jessani, Graham Emslie, Beth Kennard, Carroll Hughes, Maryse Ruberu, Nili Benazon, David Rosenberg, Michael Butkus, Marla Bartoi, Greg Clarke, David Brent, Gary Koch

Research output: Contribution to journalArticle

Abstract

Objectives: A rapidly growing empirical literature on the treatment of major depressive disorder (MDD) in youth supports the efficacy of short-term treatment with depression-specific cognitive-behavioral therapy or medication management with a selective serotonin reuptake inhibitor. These studies also identify a substantial probability of partial response and of relapse, which might be addressed by more intensive, longer-term treatments. Method: Funded by the National Institute of Mental Health, the Treatment for Adolescents With Depression Study (TADS) is a multicenter, randomized, masked effectiveness trial designed to evaluate the short-term (12-week) and long-term (36-week) effectiveness of four treatments for adolescents with MDD: fluoxetine, cognitive-behavioral therapy, their combination, and, acutely, pill placebo. A volunteer sample of 432 subjects aged 12-17 years (inclusive) with a primary DSM-IV diagnosis of MDD who are broadly representative of patients seen in clinical practice will enter the study. The primary dependent measures rated blindly by an independent evaluator are the Children's Depression Rating Scale and, for responder analysis, a dichotomized Clinical Global Impressions- Improvement score. Consistent with an intent-to-treat analysis, all patients, regardless of treatment status, return for all scheduled assessments. Results: This report describes the design of the trial, the rationale for the design choices made, and the methods used to carry out the trial. Conclusion: When completed, TADS will improve our understanding of how best to initiate treatment for adolescents with MDD.

Original languageEnglish (US)
Pages (from-to)531-542
Number of pages12
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume42
Issue number5
DOIs
StatePublished - May 2003
Externally publishedYes

Fingerprint

Depression
Major Depressive Disorder
Cognitive Therapy
Therapeutics
National Institute of Mental Health (U.S.)
Patient Advocacy
Fluoxetine
Serotonin Uptake Inhibitors
Diagnostic and Statistical Manual of Mental Disorders
Volunteers
Placebos
Recurrence

Keywords

  • Adolescence
  • Cognitive-behavioral therapy
  • Depression
  • Medication
  • Methods
  • Randomized controlled trial
  • Serotonin reuptake inhibitor
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Treatment for Adolescents with Depression Study (TADS) : Rationale, design, and methods. / March, John; Silva, Susan; Petrycki, Stephen; Curry, John; Wells, Karen; Fairbank, John; Burns, Barbara; Domino, Marisa; Vitiello, Benedetto; Severe, Joanne; Casat, Charles; Kolker, Jeanette; Feeny, Norah; Findling, Robert L; Stull, Sheridan; Baab, Susan; Waslick, Bruce; Sweeney, Michael; Kentgen, Lisa; Kandel, Rachel; Walkup, John; Ginsburg, Golda; Kastelik, Elizabeth; Koo, Hyung; Kratochvil, Christopher; May, Diane; LaGrone, Randy; Harrington, Martin; Albano, Anne Marie; Hirsch, Glenn; Knibbs, Tracey; Capili, Emlyn; Reinecke, Mark; Leventhal, Bennett; Nageotte, Catherine; Rogers, Gregory; Pathak, Sanjeev; Sallee, Floyd; Cottingham, Elizabeth; Wells, Jennifer; Rohde, Paul; Simons, Anne; Grimm, James; Hadjiyannakis, Katholiki; Weller, Elizabeth; Robins, Michele; Weller, Ronald; Jessani, Naushad; Emslie, Graham; Kennard, Beth; Hughes, Carroll; Ruberu, Maryse; Benazon, Nili; Rosenberg, David; Butkus, Michael; Bartoi, Marla; Clarke, Greg; Brent, David; Koch, Gary.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 42, No. 5, 05.2003, p. 531-542.

Research output: Contribution to journalArticle

March, J, Silva, S, Petrycki, S, Curry, J, Wells, K, Fairbank, J, Burns, B, Domino, M, Vitiello, B, Severe, J, Casat, C, Kolker, J, Feeny, N, Findling, RL, Stull, S, Baab, S, Waslick, B, Sweeney, M, Kentgen, L, Kandel, R, Walkup, J, Ginsburg, G, Kastelik, E, Koo, H, Kratochvil, C, May, D, LaGrone, R, Harrington, M, Albano, AM, Hirsch, G, Knibbs, T, Capili, E, Reinecke, M, Leventhal, B, Nageotte, C, Rogers, G, Pathak, S, Sallee, F, Cottingham, E, Wells, J, Rohde, P, Simons, A, Grimm, J, Hadjiyannakis, K, Weller, E, Robins, M, Weller, R, Jessani, N, Emslie, G, Kennard, B, Hughes, C, Ruberu, M, Benazon, N, Rosenberg, D, Butkus, M, Bartoi, M, Clarke, G, Brent, D & Koch, G 2003, 'Treatment for Adolescents with Depression Study (TADS): Rationale, design, and methods', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 42, no. 5, pp. 531-542. https://doi.org/10.1097/01.CHI.0000046839.90931.0D
March, John ; Silva, Susan ; Petrycki, Stephen ; Curry, John ; Wells, Karen ; Fairbank, John ; Burns, Barbara ; Domino, Marisa ; Vitiello, Benedetto ; Severe, Joanne ; Casat, Charles ; Kolker, Jeanette ; Feeny, Norah ; Findling, Robert L ; Stull, Sheridan ; Baab, Susan ; Waslick, Bruce ; Sweeney, Michael ; Kentgen, Lisa ; Kandel, Rachel ; Walkup, John ; Ginsburg, Golda ; Kastelik, Elizabeth ; Koo, Hyung ; Kratochvil, Christopher ; May, Diane ; LaGrone, Randy ; Harrington, Martin ; Albano, Anne Marie ; Hirsch, Glenn ; Knibbs, Tracey ; Capili, Emlyn ; Reinecke, Mark ; Leventhal, Bennett ; Nageotte, Catherine ; Rogers, Gregory ; Pathak, Sanjeev ; Sallee, Floyd ; Cottingham, Elizabeth ; Wells, Jennifer ; Rohde, Paul ; Simons, Anne ; Grimm, James ; Hadjiyannakis, Katholiki ; Weller, Elizabeth ; Robins, Michele ; Weller, Ronald ; Jessani, Naushad ; Emslie, Graham ; Kennard, Beth ; Hughes, Carroll ; Ruberu, Maryse ; Benazon, Nili ; Rosenberg, David ; Butkus, Michael ; Bartoi, Marla ; Clarke, Greg ; Brent, David ; Koch, Gary. / Treatment for Adolescents with Depression Study (TADS) : Rationale, design, and methods. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2003 ; Vol. 42, No. 5. pp. 531-542.
@article{f793b8ebbbc540339b2f0cc0491a3530,
title = "Treatment for Adolescents with Depression Study (TADS): Rationale, design, and methods",
abstract = "Objectives: A rapidly growing empirical literature on the treatment of major depressive disorder (MDD) in youth supports the efficacy of short-term treatment with depression-specific cognitive-behavioral therapy or medication management with a selective serotonin reuptake inhibitor. These studies also identify a substantial probability of partial response and of relapse, which might be addressed by more intensive, longer-term treatments. Method: Funded by the National Institute of Mental Health, the Treatment for Adolescents With Depression Study (TADS) is a multicenter, randomized, masked effectiveness trial designed to evaluate the short-term (12-week) and long-term (36-week) effectiveness of four treatments for adolescents with MDD: fluoxetine, cognitive-behavioral therapy, their combination, and, acutely, pill placebo. A volunteer sample of 432 subjects aged 12-17 years (inclusive) with a primary DSM-IV diagnosis of MDD who are broadly representative of patients seen in clinical practice will enter the study. The primary dependent measures rated blindly by an independent evaluator are the Children's Depression Rating Scale and, for responder analysis, a dichotomized Clinical Global Impressions- Improvement score. Consistent with an intent-to-treat analysis, all patients, regardless of treatment status, return for all scheduled assessments. Results: This report describes the design of the trial, the rationale for the design choices made, and the methods used to carry out the trial. Conclusion: When completed, TADS will improve our understanding of how best to initiate treatment for adolescents with MDD.",
keywords = "Adolescence, Cognitive-behavioral therapy, Depression, Medication, Methods, Randomized controlled trial, Serotonin reuptake inhibitor, Treatment",
author = "John March and Susan Silva and Stephen Petrycki and John Curry and Karen Wells and John Fairbank and Barbara Burns and Marisa Domino and Benedetto Vitiello and Joanne Severe and Charles Casat and Jeanette Kolker and Norah Feeny and Findling, {Robert L} and Sheridan Stull and Susan Baab and Bruce Waslick and Michael Sweeney and Lisa Kentgen and Rachel Kandel and John Walkup and Golda Ginsburg and Elizabeth Kastelik and Hyung Koo and Christopher Kratochvil and Diane May and Randy LaGrone and Martin Harrington and Albano, {Anne Marie} and Glenn Hirsch and Tracey Knibbs and Emlyn Capili and Mark Reinecke and Bennett Leventhal and Catherine Nageotte and Gregory Rogers and Sanjeev Pathak and Floyd Sallee and Elizabeth Cottingham and Jennifer Wells and Paul Rohde and Anne Simons and James Grimm and Katholiki Hadjiyannakis and Elizabeth Weller and Michele Robins and Ronald Weller and Naushad Jessani and Graham Emslie and Beth Kennard and Carroll Hughes and Maryse Ruberu and Nili Benazon and David Rosenberg and Michael Butkus and Marla Bartoi and Greg Clarke and David Brent and Gary Koch",
year = "2003",
month = "5",
doi = "10.1097/01.CHI.0000046839.90931.0D",
language = "English (US)",
volume = "42",
pages = "531--542",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Treatment for Adolescents with Depression Study (TADS)

T2 - Rationale, design, and methods

AU - March, John

AU - Silva, Susan

AU - Petrycki, Stephen

AU - Curry, John

AU - Wells, Karen

AU - Fairbank, John

AU - Burns, Barbara

AU - Domino, Marisa

AU - Vitiello, Benedetto

AU - Severe, Joanne

AU - Casat, Charles

AU - Kolker, Jeanette

AU - Feeny, Norah

AU - Findling, Robert L

AU - Stull, Sheridan

AU - Baab, Susan

AU - Waslick, Bruce

AU - Sweeney, Michael

AU - Kentgen, Lisa

AU - Kandel, Rachel

AU - Walkup, John

AU - Ginsburg, Golda

AU - Kastelik, Elizabeth

AU - Koo, Hyung

AU - Kratochvil, Christopher

AU - May, Diane

AU - LaGrone, Randy

AU - Harrington, Martin

AU - Albano, Anne Marie

AU - Hirsch, Glenn

AU - Knibbs, Tracey

AU - Capili, Emlyn

AU - Reinecke, Mark

AU - Leventhal, Bennett

AU - Nageotte, Catherine

AU - Rogers, Gregory

AU - Pathak, Sanjeev

AU - Sallee, Floyd

AU - Cottingham, Elizabeth

AU - Wells, Jennifer

AU - Rohde, Paul

AU - Simons, Anne

AU - Grimm, James

AU - Hadjiyannakis, Katholiki

AU - Weller, Elizabeth

AU - Robins, Michele

AU - Weller, Ronald

AU - Jessani, Naushad

AU - Emslie, Graham

AU - Kennard, Beth

AU - Hughes, Carroll

AU - Ruberu, Maryse

AU - Benazon, Nili

AU - Rosenberg, David

AU - Butkus, Michael

AU - Bartoi, Marla

AU - Clarke, Greg

AU - Brent, David

AU - Koch, Gary

PY - 2003/5

Y1 - 2003/5

N2 - Objectives: A rapidly growing empirical literature on the treatment of major depressive disorder (MDD) in youth supports the efficacy of short-term treatment with depression-specific cognitive-behavioral therapy or medication management with a selective serotonin reuptake inhibitor. These studies also identify a substantial probability of partial response and of relapse, which might be addressed by more intensive, longer-term treatments. Method: Funded by the National Institute of Mental Health, the Treatment for Adolescents With Depression Study (TADS) is a multicenter, randomized, masked effectiveness trial designed to evaluate the short-term (12-week) and long-term (36-week) effectiveness of four treatments for adolescents with MDD: fluoxetine, cognitive-behavioral therapy, their combination, and, acutely, pill placebo. A volunteer sample of 432 subjects aged 12-17 years (inclusive) with a primary DSM-IV diagnosis of MDD who are broadly representative of patients seen in clinical practice will enter the study. The primary dependent measures rated blindly by an independent evaluator are the Children's Depression Rating Scale and, for responder analysis, a dichotomized Clinical Global Impressions- Improvement score. Consistent with an intent-to-treat analysis, all patients, regardless of treatment status, return for all scheduled assessments. Results: This report describes the design of the trial, the rationale for the design choices made, and the methods used to carry out the trial. Conclusion: When completed, TADS will improve our understanding of how best to initiate treatment for adolescents with MDD.

AB - Objectives: A rapidly growing empirical literature on the treatment of major depressive disorder (MDD) in youth supports the efficacy of short-term treatment with depression-specific cognitive-behavioral therapy or medication management with a selective serotonin reuptake inhibitor. These studies also identify a substantial probability of partial response and of relapse, which might be addressed by more intensive, longer-term treatments. Method: Funded by the National Institute of Mental Health, the Treatment for Adolescents With Depression Study (TADS) is a multicenter, randomized, masked effectiveness trial designed to evaluate the short-term (12-week) and long-term (36-week) effectiveness of four treatments for adolescents with MDD: fluoxetine, cognitive-behavioral therapy, their combination, and, acutely, pill placebo. A volunteer sample of 432 subjects aged 12-17 years (inclusive) with a primary DSM-IV diagnosis of MDD who are broadly representative of patients seen in clinical practice will enter the study. The primary dependent measures rated blindly by an independent evaluator are the Children's Depression Rating Scale and, for responder analysis, a dichotomized Clinical Global Impressions- Improvement score. Consistent with an intent-to-treat analysis, all patients, regardless of treatment status, return for all scheduled assessments. Results: This report describes the design of the trial, the rationale for the design choices made, and the methods used to carry out the trial. Conclusion: When completed, TADS will improve our understanding of how best to initiate treatment for adolescents with MDD.

KW - Adolescence

KW - Cognitive-behavioral therapy

KW - Depression

KW - Medication

KW - Methods

KW - Randomized controlled trial

KW - Serotonin reuptake inhibitor

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0042783158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042783158&partnerID=8YFLogxK

U2 - 10.1097/01.CHI.0000046839.90931.0D

DO - 10.1097/01.CHI.0000046839.90931.0D

M3 - Article

C2 - 12707557

AN - SCOPUS:0042783158

VL - 42

SP - 531

EP - 542

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 5

ER -